110 related articles for article (PubMed ID: 28402713)
1. Optical Biometry Derived Axial Length Measurements Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema.
Kymionis GD; Giarmoukakis A; Apostolidi IK; Blazaki SV; Tsoulnaras KI; Moschandrea J; Panagopoulou S; Tsilimbaris MK
Semin Ophthalmol; 2018; 33(4):488-491. PubMed ID: 28402713
[TBL] [Abstract][Full Text] [Related]
2. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
[TBL] [Abstract][Full Text] [Related]
3. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
[TBL] [Abstract][Full Text] [Related]
4. Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections.
Osaka R; Muraoka Y; Miwa Y; Manabe K; Kobayashi M; Takasago Y; Ooto S; Murakami T; Suzuma K; Iida Y; Tsujikawa A
Ophthalmologica; 2018; 239(1):27-35. PubMed ID: 28946138
[TBL] [Abstract][Full Text] [Related]
5. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
[TBL] [Abstract][Full Text] [Related]
6. Macular cystic changes as predictive factor for the recurrence of macular oedema in branch retinal vein occlusion.
Tilgner E; Dalcegio Favretto M; Tuisl M; Wiedemann P; Rehak M
Acta Ophthalmol; 2017 Nov; 95(7):e592-e596. PubMed ID: 28266152
[TBL] [Abstract][Full Text] [Related]
7. QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANALYSIS OF RETINAL DEGENERATIVE CHANGES IN DIABETIC MACULAR EDEMA AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Boiko EV; Maltsev DS
Retina; 2018 Jul; 38(7):1324-1330. PubMed ID: 28492427
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two individualized treatment regimens with ranibizumab for diabetic macular edema.
Ebneter A; Waldmeier D; Zysset-Burri DC; Wolf S; Zinkernagel MS
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):549-555. PubMed ID: 27714513
[TBL] [Abstract][Full Text] [Related]
9. Optical Coherence Tomography Angiography Analysis of the Foveal Avascular Zone and Macular Vessel Density After Anti-VEGF Therapy in Eyes With Diabetic Macular Edema and Retinal Vein Occlusion.
Ghasemi Falavarjani K; Iafe NA; Hubschman JP; Tsui I; Sadda SR; Sarraf D
Invest Ophthalmol Vis Sci; 2017 Jan; 58(1):30-34. PubMed ID: 28114569
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
Kim M; Jeong S; Sagong M
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
[TBL] [Abstract][Full Text] [Related]
11. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
[TBL] [Abstract][Full Text] [Related]
12. Impact of serous retinal detachment on the efficacy of ranibizumab in diabetic macular oedema.
Qu-Knafo LM; Fajnkuchen F; Sarda V; Boubaya M; Levy V; Chaine G; Giocanti-Auregan A
Acta Ophthalmol; 2017 Aug; 95(5):e434-e435. PubMed ID: 26823130
[No Abstract] [Full Text] [Related]
13. Optical biometry-based axial length alterations after intravitreal dexamethasone implant.
Ozal SA; Kupelı A; Ozal E; Gurlu V
Arq Bras Oftalmol; 2019; 82(3):195-199. PubMed ID: 30810616
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
[TBL] [Abstract][Full Text] [Related]
15. Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment.
Karst SG; Lammer J; Mitsch C; Schober M; Mehta J; Scholda C; Kundi M; Kriechbaum K; Schmidt-Erfurth U
Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):49-58. PubMed ID: 29080915
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the New "SAVE" Protocol in Diabetic Macular Edema Over the Course of Anti-VEGF Treatment.
Reznicek L; Bolz M; Garip A; Kampik A; Kernt M; Mayer WJ
Curr Eye Res; 2016 Aug; 41(8):1082-1086. PubMed ID: 26580417
[TBL] [Abstract][Full Text] [Related]
17. Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration.
Kanadani TCM; Dos Reis Veloso CE; Dorairaj S; Nehemy MB
Ophthalmic Res; 2017; 58(1):18-26. PubMed ID: 28301850
[TBL] [Abstract][Full Text] [Related]
18. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
19. Optical Coherence Tomography Angiography of DME and Its Association with Anti-VEGF Treatment Response.
Lee J; Moon BG; Cho AR; Yoon YH
Ophthalmology; 2016 Nov; 123(11):2368-2375. PubMed ID: 27613201
[TBL] [Abstract][Full Text] [Related]
20. Diameter of retinal vessels in patients with diabetic macular edema is not altered by intravitreal ranibizumab (lucentis).
Terai N; Haustein M; Siegel A; Stodtmeister R; Pillunat LE; Sandner D
Retina; 2014 Jul; 34(7):1466-72. PubMed ID: 24457978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
